肿瘤优先DNA检测作为转移性前列腺癌胚系筛查的门径
研究基于前瞻性PROMPT研究452例转移性前列腺癌患者,评估肿瘤优先工作流(TFW)检测胚系致病变异(gPV)的性能,并与模型化家族史(FH)转诊策略比较。结果显示TFW转诊了22/36(61%)携带者,所有高风险基因变异均被识别,且较FH策略检出更多携带者、PPV更高、每检出成本更低。
要点
- TFW转诊了61%的gPV携带者,并识别所有高风险基因变异。
- TFW较FH策略检出更多携带者(22 vs 8),PPV更高(51% vs 13%)。
- TFW每检出gPV的估计诊断成本为€998,FH策略为€12,246。
核心结论
- TFW是转移性前列腺癌胚系致病变异检测的高效且临床实用的策略,能完整识别高风险可操作携带者。
研究设计与样本
- 分析前瞻性PROMPT研究中452例转移性前列腺癌患者的配对肿瘤与胚系测序数据,以胚系检测为参考标准评估TFW性能。
主要发现
- 胚系检测在36/452(7.8%)患者中检出gPV,TFW技术敏感性为97%。
- 按预设TFW转诊标准,22/36(61%)携带者被转诊进行胚系检测,所有高风险基因(BRCA2、BRCA1、PALB2)变异均被识别。
- 与模型化FH转诊相比,TFW检出显著更多携带者(22 vs 8;p < 0.001),PPV更高(51% vs 13%),需检测人数更低(2.0 vs 7.9)。
- 每检出gPV的估计诊断成本为€998,FH策略为€12,246。
关键数值与推荐
- TFW转诊标准下61%(22/36)gPV携带者被转诊,所有BRCA2、BRCA1、PALB2变异均被识别。
- TFW与FH策略比较:检出携带者22 vs 8(p < 0.001),PPV 51% vs 13%,需检测人数2.0 vs 7.9,每检出gPV成本€998 vs €12,246。
临床怎么用
- 当无法对所有转移性前列腺癌患者进行整合肿瘤与胚系检测时,TFW应被视为常规精准肿瘤学实践中首选的转诊策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Integrated tumour and germline testing is recommended for all patients with metastatic prostate cancer (mPCa), yet real-world implementation varies widely. Use of tumour analysis to stratify patients for germline testing (tumour-first workflow (TFW)) has emerged as an efficient triage strategy, but its performance relative to family history (FH)-based referral remains insufficiently characterised. METHODS: We analysed paired tumour and germline sequencing data from 452 patients enrolled in the prospective PROMPT study. TFW performance for detecting germline pathogenic variants (gPVs) in BRCA2, BRCA1, PALB2, ATM and CHEK2 was assessed using germline testing as the reference standard. Diagnostic performance was compared with a modelled FH-based referral strategy. Diagnostic cost analysis was evaluated using standard Dutch diagnostic tariffs. RESULTS: Germline testing identified gPVs in 36/452 (7.8%) patients. Technical sensitivity was 97%. Under the predefined TWF referral criteria, 22/36 carriers (61%) were referred for germline testing. All high-risk gene variants (BRCA2, BRCA1, PALB2) were identified. Compared with modelled FH-based referral, TFW identified significantly more carriers (22 vs 8; p < 0.001), with markedly higher PPV (51% vs 13%) and lower number needed to test (2.0 vs 7.9). The estimated diagnostic cost per detected gPV was €998 vs €12,246. DISCUSSION AND CONCLUSION: TFW is an efficient and clinically pragmatic strategy for gPVs detection in mPCa, with complete identification of high-risk carriers actionable for treatment and cascade testing. TFW substantially outperforms FH-based referral and should be considered the preferred triage approach in routine precision oncology practice whenever integrated tumour and germline testing of all patients with mPCa is not feasible.
引用
- Kloots ISH, Kets CM, Schuurs-Hoeijmakers J, et al. Tumour-first DNA testing as a gateway to germline screening in patients with metastatic prostate cancer. Eur J Cancer. 2026. PMID: 42800309. doi:10.1016/j.ejca.2026.117060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。